SNBL USA, the experts in primate research, has announced the appointment of Janet Kelly, MSc, as SNBL USA’s director of business development for the European region. Kelly, who is based near Paris, will be responsible for driving the growth of SNBL USA´s European business, including fostering positive relationships with new and current customers.
A registered European toxicologist, Kelly joins SNBL USA from CJS Scientific, Ltd., where she served as director and consultant to the pharmaceutical and agrochemical industries in the fields of nonclinical development, toxicology, translational medicine and dossier preparation. Prior to CJS Scientific, Kelly held many positions at Covance Laboratories including director of operations at Covance R&D (Shanghai, China), associate director of business development, head of operations and head of toxicology study direction. She was also a member of a number of scientific and welfare groups in the UK and Europe.
“With more than 26 years of industry experience, Janet has held a number of key posts with progressively responsible roles in study direction, business development and operations,” said Mark Crane, SNBL USA vice president of business development. “Her preclinical market understanding, experiences and direct knowledge of the rapidly changing European market dynamics will be of great value to SNBL USA and all its customers. I am excited to have Janet on our team.”
For additional information regarding SNBL USA services and capabilities, contact SNBL USA at +1.425.322.1950 or info@snblusa.com.
About SNBL USA, Ltd.
Headquartered in Everett, Wash., SNBL USA, Ltd. offers a unique range of safety assessment services to fulfill its commitment to help free patients from suffering. Managed and operated by a team world renowned for its wide-ranging nonhuman primate (NHP) experience and expertise, SNBL offers programs ranging from regulatory toxicology to customized study designs. SNBL’s specialized capabilities include safety assessment of biologics, reproductive toxicology, cardiovascular, respiratory and CNS pharmacology, immunotoxicology and carcinogenicity.
